Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to confirm that, further to the Company’s announcement on 18 October 2022 regarding the Company’s Placing and the Open Offer, the Open Offer Circular was posted yesterday. A copy of the Circular will be available shortly on the Company website.
Capitalised terms used but not otherwise defined in the text of this announcement shall have the meaning given to them in the Company’s announcements on the 18 October 2022.